DEF: scPharmaceuticals Announces 2025 Annual Meeting of Stockholders
Sentiment:
Proxy Statement
scPharmaceuticals will hold its 2025 Annual Meeting of Stockholders online on June 3, 2025, to elect directors, ratify the appointment of its accounting firm, and approve executive compensation.
Summary
- scPharmaceuticals Inc. will hold its 2025 Annual Meeting of Stockholders online on June 3, 2025, at 12:30 p.m. Eastern Time.
- Stockholders of record as of April 7, 2025, are entitled to vote.
- The meeting will address the election of three Class II directors (William T. Abraham, M.D., Mette Kirstine Agger, and Minnie Baylor-Henry), ratification of RSM US LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, and an advisory vote on executive compensation.
- The board of directors recommends voting for the election of the director nominees, for the ratification of RSM US LLP, and for the approval of the compensation of the named executive officers.
- As of April 7, 2025, there were 50,283,925 shares of common stock outstanding, requiring 25,141,963 shares for a quorum.
Sentiment
Score: 7
Explanation: The document is a standard proxy statement, which is generally neutral in tone. It provides necessary information for shareholders to make informed decisions. The company's commitment to ESG and ethical practices contributes to a slightly positive sentiment.
Positives
- The board of directors is committed to ensuring the board is comprised of a group of directors who collectively provide a significant breadth of experience, knowledge and ability to effectively represent the interest of stockholders.
- The company has a Code of Business Conduct and Ethics in place.
- The company is committed to increasing transparency and further identifying issues that may have a material effect on corporate strategy, risks, opportunities or performance.
- The company offers a patient assistance program that includes copay support and offers FUROSCIX for no or low cost for financially eligible patients.
- The Company has been recognized by the Boston Business Journals Best Places to Work list for companies of our size in 2020, 2021, 2022, 2024, and 2025.
Risks
- The document mentions risks related to the company's financial condition, development and commercialization activities, operations, strategic direction, and intellectual property, as discussed in the Annual Report on Form 10-K.
Future Outlook
The company intends to file a proxy statement and WHITE proxy card with the SEC in connection with the solicitation of proxies for its 2026 Annual Meeting.
Industry Context
This document is a standard proxy statement, which is a common practice for publicly traded companies to inform shareholders and solicit votes on key corporate matters. The proposals are typical for annual meetings.
Comparison to Industry Standards
- The director compensation structure, including cash retainers and equity grants, is generally in line with industry practices for similarly sized companies.
- The use of an independent compensation consultant (Pearl Meyer) is a common practice to ensure executive compensation is aligned with market rates and performance.
- The company's corporate governance practices, such as having independent directors and audit, compensation, and nominating committees, align with Nasdaq listing requirements and best practices.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Director Independence | The board of directors has determined that all members of the board, excluding John H. Tucker, are independent. | As of the date of this Proxy Statement | Ensures independent oversight of management. |
| Non-Employee Director Compensation Policy | In 2025, our board of directors increased the amount of cash compensation our non-executive chairman may earn in a fiscal year. | 2025 | Attract and retain highly-qualified non-employee directors. |
Stakeholder Impact
- Shareholders: The document provides information necessary for shareholders to vote on key company matters.
- Employees: The document outlines executive compensation and benefits, which impacts employee morale and retention.
- Customers: The company's commitment to patient access and affordability impacts customers' ability to access medications.
- Suppliers: The company's ethical and compliance policies impact relationships with suppliers.
- Creditors: The company's financial performance and risk management policies impact its creditworthiness.
Next Steps
- Stockholders are encouraged to read the Proxy Statement and submit their proxy or voting instructions as soon as possible.
- Stockholders can vote at the Annual Meeting, via the Internet, by mail, or by telephone.
- The company will announce preliminary results at the Annual Meeting and report final results by filing a Form 8-K.
Key Dates
| Date | Description |
|---|---|
| 2013 | RSM US LLP has audited our financial statements for each fiscal year since 2013. |
| March 7, 2017 | John H. Tucker was awarded an option to purchase 496,674 shares of our common stock under our 2014 Plan. |
| November 17, 2017 | We entered into employment agreements with each of our named executive officers, Mr. Tucker and Ms. Nokes, on November 17, 2017 and December 12, 2019, respectively. |
| November 2017 | Closing of our initial public offering in November 2017, no additional equity awards have been or will be made under our 2014 Plan. |
| January 17, 2018 | Mr. Tucker was awarded an option to purchase 100,000 shares of our common stock under our 2017 Plan. |
| June 2018 | Frederick M. Hudson has served as a member of our board of directors since June 2018. |
| July 2018 | Minnie Baylor-Henry has served as a member of our board of directors since July 2018. |
| July 17, 2018 | Ms. Nokes was awarded an option to purchase 13,850 shares of our common stock under our 2017 Plan. |
| February 25, 2019 | Mr. Tucker was awarded an option to purchase 84,500 shares of our common stock under our 2017 Plan. |
| December 12, 2019 | We entered into employment agreements with each of our named executive officers, Mr. Tucker and Ms. Nokes, on November 17, 2017 and December 12, 2019, respectively. |
| January 10, 2020 | Mr. Tucker was awarded an option to purchase 255,000 shares of our common stock under our 2017 Plan. |
| July 2020 | Sara Bonstein has served as a member of our board of directors since July 2020. |
| January 25, 2021 | Mr. Tucker was awarded an option to purchase 224,100 shares of our common stock under our 2017 Plan. |
| February 2021 | William T. Abraham, MD, FACP, FACC, FAHA, FESC, FRCPE has served as a member of our board of directors since February 2021. |
| January 31, 2022 | Mr. Tucker was awarded an option to purchase 249,000 shares of our common stock under our 2017 Plan. |
| December 15, 2022 | Ms. Nokes was awarded an option to purchase 85,750 shares of our common stock under our 2017 Plan. |
| January 19, 2023 | Mr. Tucker was awarded an option to purchase 100,000 shares of our common stock under our 2017 Plan. |
| January 31, 2023 | Our board of directors adopted our 2023 Employment Inducement Award Plan (the Inducement Plan) providing for the issuance of up to 500,000 shares of our common stock as inducement awards in accordance with Rule 5635(c)(4) of the Nasdaq Listing Standards. |
| January 18, 2024 | Mr. Tucker was awarded an option to purchase 170,340 shares of our common stock under our 2017 Plan. |
| December 31, 2024 | Information as of December 31, 2024 regarding shares of common stock that may be issued under our equity compensation plans. |
| April 7, 2025 | Record date for the Annual Meeting; 50,283,925 shares of common stock outstanding. |
| April 21, 2025 | This Proxy Statement is being made available to stockholders beginning on April 21, 2025. |
| April 24, 2025 | The mailing of the Notice to our stockholders is scheduled to begin on or about April 24, 2025. |
| June 2, 2025 | Proxies submitted by telephone or Internet prior to the Annual Meeting must be received by 11:59 p.m. Eastern Time on June 2, 2025. |
| June 3, 2025 | 2025 Annual Meeting of Stockholders to be held online at 12:30 p.m. Eastern Time. |
| February 3, 2026 | For stockholder proposals to be brought before the 2026 Annual Meeting of Stockholders, the required notice must be received by our Corporate Secretary at our headquarters no earlier than February 3, 2026. |
| March 5, 2026 | For stockholder proposals to be brought before the 2026 Annual Meeting of Stockholders, the required notice must be received by our Corporate Secretary at our headquarters no later than March 5, 2026. |
| December 25, 2025 | For such proposals to be included in our proxy materials relating to our 2026 Annual Meeting of Stockholders, all applicable requirements of Rule 14a-8 must be satisfied and we must receive such proposals no later than December 25, 2025. |
Keywords
Annual Meeting, Stockholders, Directors, Proxy Statement, Executive Compensation, RSM US LLP, scPharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.